| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1772 | |
| Phytochemical name or plant extracts | Horse chestnut extract (HCE) | |
| PMID | 22451355 | |
| Literature evidence | In conclusion, the present study has assessed the in vitro antiproliferative/antiangiogenic potential of HCE | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Extract | |
| Source of phytochemicals or plant Extracts | Aesculus hippocastanum | |
| Geographical availability | Albania, Bulgaria, Greece, Turkey, Turkmenistan, Yugoslavia | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | MMP, VEGF | |
| Gene or Protein evidence | Furthermore, HCE inhibited migration of human umbilical vein endothelial cells as well as decreased secretion of matrix metalloproteinase and vascular endothelial growth factor. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | In conclusion, the present study has assessed the in vitro antiproliferative/antiangiogenic potential of HCE. These results generate a rationale for in vivo efficacy studies with horse chestnut in preclinical cancer models. | |
| Cell line/ mice model | Jurkat, CEM, HeLa, and MCF-7 | |
| Additional information | NA | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:781594-1 | |
| Safety | NA |